Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

The Correlation of Brain Natriuretic Peptide (BNP), Pulmonary Arterial Pressure, and St. George Respiratory Questionnaire (SGRQ) and Their Changes with a Trial of an Angiotensin Converting Enzyme Inhibitor

폐동맥고혈압이 동반된 만성폐쇄성폐질환 환자에서 혈중 Brain Natriuretic Peptide, 폐동맥압 및 St. George Respiratory Questionnaire의 상관성과 안지오텐신전환효소억제제 치료 효과

  • Kim, Myung-A (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Deog-Kyeom (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Chang-Hoon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Chung, Hee-Soon (Department of Internal Medicine, Seoul National University College of Medicine)
  • 김명아 (서울대학교 의과대학 내과학교실) ;
  • 김덕겸 (서울대학교 의과대학 내과학교실) ;
  • 이창훈 (서울대학교 의과대학 내과학교실) ;
  • 정희순 (서울대학교 의과대학 내과학교실)
  • Received : 2010.04.15
  • Accepted : 2010.04.21
  • Published : 2010.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Pulmonary hypertension is considered as a poor prognosis factor in patients with chronic obstructive pulmonary disease (COPD). There has been reported brain natriuretic peptide (pro-BNP) is related with increased right ventricular (RV) workloads. However, there are few studies that evaluate the relationship between BNP and pulmonary arterial pressure (PAP), RV function and St. George Respiratory Questionnaire (SGRQ) score in patients with COPD, and the effects of angiotensin converting enzyme inhibitor (ACEI) on these parameters. Methods: Pulmonary function test, echocardiography, blood BNP, and SGRQ score were evaluated in stabilized moderate degree COPD patients ($FEV_1$/FVC< 70%, $50%{\leq}FEV_1$ < 80%) aged 45 years and over, without worsening of symptoms within recent 3 months. After treating with ramipril 10 mg for 3 months, the same evaluation was repeated. Results: Twenty-two patients were included in this study. BNP was significantly correlated with PAP (Pearson coefficient ${\rho}=0.51$, p=0.02), but not with RV ejection fraction (EF) and predicted $FEV_1%$. The values for predicted $FEV_1%$ showed significant correlation with SGRQ total score and activity score, but not with BNP or PAP. After ramipril treatment, PAP showed significant decrease ($42.8{\pm}8.1$ vs. $34.5{\pm}4.5mm$ Hg p=0.0003), tricuspid annular plane systolic excursion significant increase ($21.5{\pm}3.3$ vs. $22.7{\pm}3.1mm$ p=0.009). BNP showed a tendency to decrease without statistical significance ($40.8{\pm}59.6$ vs. $18.0{\pm}9.1pg/mL$ p=0.55). SGRQ scores showed no significant change. Conclusion: BNP showed significant correlation with resting PAP, which means BNP could be used as markers for pulmonary hypertension. Treatment with ACEI didn't show significant change in the level of BNP, while pulmonary hypertension and RV function were improved.

Keywords

References

  1. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-94. https://doi.org/10.1164/rccm.200401-006OC
  2. Hammarstrom E, Wranne B, Pinto FJ, Puryear J, Popp RL. Tricuspid annular motion. J Am Soc Echocardiogr 1991;4:131-9. https://doi.org/10.1016/S0894-7317(14)80524-5
  3. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984;107:526-31. https://doi.org/10.1016/0002-8703(84)90095-4
  4. Ghio S, Recusani F, Klersy C, Sebastiani R, Laudisa ML, Campana C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000;85:837-42. https://doi.org/10.1016/S0002-9149(99)00877-2
  5. Passino C, Maria Sironi A, Favilli B, Poletti R, Prontera C, Ripoli A, et al. Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. Int J Cardiol 2005;104:39-45. https://doi.org/10.1016/j.ijcard.2004.09.008
  6. Mariano-Goulart D, Eberle MC, Boudousq V, Hejazi- Moughari A, Piot C, Caderas de Kerleau C, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 2003;5:481-8. https://doi.org/10.1016/S1388-9842(03)00041-2
  7. Troisi F, Greco S, Brunetti ND, Di Biase M. Right heart dysfunction assessed with echography, B-type natriuretic peptide and cardiopulmonary test in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 2008;9:672-6. https://doi.org/10.2459/JCM.0b013e3282f331eb
  8. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23. https://doi.org/10.1016/S0002-8703(98)70054-7
  9. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8. https://doi.org/10.1067/mem.2002.121483
  10. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76:232-7. https://doi.org/10.1136/hrt.76.3.232
  11. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999;230:132-42.
  12. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91. https://doi.org/10.1016/S0735-1097(00)01157-8
  13. Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000;301:19-30. https://doi.org/10.1016/S0009-8981(00)00312-0
  14. Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartiere JM, Chavelas C, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with nonmassive pulmonary embolism. Intensive Care Med 2007;33:286-92. https://doi.org/10.1007/s00134-006-0482-1
  15. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet 1979;1:1213-5.
  16. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350: 1349-53. https://doi.org/10.1016/S0140-6736(97)06031-5
  17. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptideas a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32. https://doi.org/10.1016/S0002-8703(98)70041-9
  18. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88. https://doi.org/10.1515/CCLM.2001.093
  19. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004;6:359-63. https://doi.org/10.1016/j.ejheart.2004.01.008
  20. Reesink HJ, Tulevski, II, Marcus JT, Boomsma F, Kloek JJ, Vonk Noordegraaf A, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84:537-43. https://doi.org/10.1016/j.athoracsur.2007.04.006
  21. Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006;97:1386-90. https://doi.org/10.1016/j.amjcard.2005.11.075
  22. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009;48:503-12. https://doi.org/10.2169/internalmedicine.48.1701
  23. Kim MA, Kim SH, Zo JH, Hwangbo B, Lee JH, Chung HS. Right heart dysfunction in post-tuberculosis emphysema. Int J Tuberc Lung Dis 2004;8:1120-6.
  24. Gemici G, Erdim R, Celiker A, Tokay S, Ones T, Inanir S, et al. B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther 2008;25:674-80. https://doi.org/10.1007/s12325-008-0067-1
  25. King L, Wilkins MR. Natriuretic peptide receptors and the heart. Heart 2002;87:314-5. https://doi.org/10.1136/heart.87.4.314
  26. Lang CC, Coutie WJ, Struthers AD, Dhillon DP, Winter JH, Lipworth BJ. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 1992;83:529-33. https://doi.org/10.1042/cs0830529
  27. Yetkin O, Hacievliyagil SS, Gunen H. Assessment of B-type natriuretic peptide in patients with pneumonia. Int J Clin Pract 2008;62:488-91.
  28. He Q, LaPointe MC. Interleukin-1betaregulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999;33:283-9. https://doi.org/10.1161/01.HYP.33.1.283
  29. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community- acquired pneumonia. J Intern Med 2005;258: 391-3. https://doi.org/10.1111/j.1365-2796.2005.01540.x
  30. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173:744-50. https://doi.org/10.1164/rccm.200510-1545OC
  31. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 2007;12:23-36. https://doi.org/10.1007/s10741-007-9002-9
  32. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70. https://doi.org/10.1016/j.jacc.2003.09.051
  33. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94. https://doi.org/10.1378/chest.07-1959
  34. Maeder MT, Brutsche MH, Christ A, Reichlin T, Staub D, Noveanu M, et al. Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. Respir Med 2009;103:1337-45. https://doi.org/10.1016/j.rmed.2009.03.015
  35. Rubin LJ. Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension. Clin Chest Med 1983;4:309-19.
  36. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35. https://doi.org/10.1056/NEJM198706043162301
  37. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302. https://doi.org/10.1056/NEJM199108013250501
  38. Di Marco F, Guazzi M, Vicenzi M, Santus P, Cazzola M, Pappalettera M, et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm Pharmacol Ther 2010;23:159-64. https://doi.org/10.1016/j.pupt.2010.01.004
  39. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45. https://doi.org/10.1186/1465-9921-10-45

Cited by

  1. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review vol.17, pp.None, 2010, https://doi.org/10.1186/s12890-016-0345-7